Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Siliq US Approval Expected To Make Little Dent In Valeant Debt Mountain

Executive Summary

A Black Box warning on suicidal ideation and behavior, a REM program and a Medication Guide may hold back the sales growth of Valeant’s new psoriasis therapy in the US, Siliq, following its Feb. 15 approval, although the drug has been associated with high levels of total skin clearance, a finding that could differentiate it from competing products.

You may also be interested in...



Valeant On Track With Debt-Reduction Goals, But Will It Be Enough?

The troubled firm has pushed back its greatest debt burden until 2020, but new products are unlikely to fill sales gap. Valeant says its GI unit is showing positive signs and that a restructuring of the derm commercial unit is nearing completion.

Siliq Probably Isn't The Light At The End Of Valeant's Tunnel

Valeant is touting Siliq to lead new product growth, but the drug's significant safety concerns in a competitive psoriasis market likely will offset efficacy advantages it could offer.

Valeant’s Brodalumab Delayed By FDA As REMS Is Negotiated

FDA notified the company the US review goal date for the psoriasis pill has been extended three months from Nov. 16 to Feb. 16.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel